An orthogonally activatable CRISPR-Cas13d nanoprodrug to reverse chemoresistance for enhanced chemo-photodynamic therapy. Issue 15 (28th March 2023)
- Record Type:
- Journal Article
- Title:
- An orthogonally activatable CRISPR-Cas13d nanoprodrug to reverse chemoresistance for enhanced chemo-photodynamic therapy. Issue 15 (28th March 2023)
- Main Title:
- An orthogonally activatable CRISPR-Cas13d nanoprodrug to reverse chemoresistance for enhanced chemo-photodynamic therapy
- Authors:
- Liu, Zheng
Feng, Zhiyuan
Chen, Mohan
Zhan, Jiayin
Wu, Rong
Shi, Yang
Xue, Yunsheng
Liu, Ran
Zhu, Jun-Jie
Zhang, Jingjing - Abstract:
- Abstract : A logic-gated CRISPR-Cas13d-based nanoprodrug was rationally designed for orthogonal photomodulation of gene editing and prodrug release for enhanced chemo-photodynamic therapy. Abstract : Orthogonal therapy that combines CRISPR-based gene editing and prodrug-based chemotherapy is a promising approach to combat multidrug-resistant cancer. However, its potency to precisely regulate different therapeutic modalities in vivo is limited due to the lack of an integrated platform with high spatiotemporal resolution. Taking advantage of CRISPR technology, a Pt(iv )-based prodrug and orthogonal emissive upconversion nanoparticles (UCNPs), we herein rationally designed the first logic-gated CRISPR-Cas13d-based nanoprodrug for orthogonal photomodulation of gene editing and prodrug release for enhanced cancer therapy. The nanoprodrug (URL) was constructed by encapsulating a green light-activatable Pt(iv ) prodrug and UV light-activatable Cas13d gene editing tool into UCNPs. We demonstrated that URL maintained excellent orthogonal emission behaviors under 808 and 980 nm excitations, allowing wavelength-selective photoactivation of Cas13d and the prodrug for downregulation of the resistance-related gene and induction of chemo-photodynamic therapy, respectively. Moreover, the photomodulation superiority of URL for overcoming drug resistance was highlighted by integrating it with a Boolean logic gate for programmable modulation of multiple cell behaviors. Importantly, in vivoAbstract : A logic-gated CRISPR-Cas13d-based nanoprodrug was rationally designed for orthogonal photomodulation of gene editing and prodrug release for enhanced chemo-photodynamic therapy. Abstract : Orthogonal therapy that combines CRISPR-based gene editing and prodrug-based chemotherapy is a promising approach to combat multidrug-resistant cancer. However, its potency to precisely regulate different therapeutic modalities in vivo is limited due to the lack of an integrated platform with high spatiotemporal resolution. Taking advantage of CRISPR technology, a Pt(iv )-based prodrug and orthogonal emissive upconversion nanoparticles (UCNPs), we herein rationally designed the first logic-gated CRISPR-Cas13d-based nanoprodrug for orthogonal photomodulation of gene editing and prodrug release for enhanced cancer therapy. The nanoprodrug (URL) was constructed by encapsulating a green light-activatable Pt(iv ) prodrug and UV light-activatable Cas13d gene editing tool into UCNPs. We demonstrated that URL maintained excellent orthogonal emission behaviors under 808 and 980 nm excitations, allowing wavelength-selective photoactivation of Cas13d and the prodrug for downregulation of the resistance-related gene and induction of chemo-photodynamic therapy, respectively. Moreover, the photomodulation superiority of URL for overcoming drug resistance was highlighted by integrating it with a Boolean logic gate for programmable modulation of multiple cell behaviors. Importantly, in vivo studies demonstrated that URL can promote Pt(iv ) prodrug activation and ROS generation and massively induce on-target drug accumulation by Cas13d-mediated drug resistance attenuation, delivering an ultimate chemo-photodynamic therapeutic performance in efficiently eradicating primary tumors and preventing further liver metastasis. Collectively, our results suggest that URL expands the Cas13d-based genome editing toolbox into prodrug nanomedicine and accelerates the discovery of new orthogonal therapeutic approaches. … (more)
- Is Part Of:
- Chemical science. Volume 14:Issue 15(2023)
- Journal:
- Chemical science
- Issue:
- Volume 14:Issue 15(2023)
- Issue Display:
- Volume 14, Issue 15 (2023)
- Year:
- 2023
- Volume:
- 14
- Issue:
- 15
- Issue Sort Value:
- 2023-0014-0015-0000
- Page Start:
- 4102
- Page End:
- 4113
- Publication Date:
- 2023-03-28
- Subjects:
- Chemistry -- Periodicals
540.5 - Journal URLs:
- http://pubs.rsc.org/en/Journals/JournalIssues/SC ↗
http://www.rsc.org/ ↗ - DOI:
- 10.1039/d3sc00020f ↗
- Languages:
- English
- ISSNs:
- 2041-6520
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 3151.490000
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 26911.xml